Table 3 Summary of ongoing or unpublished clinical trials utilising DNA vaccines for prostate cancer

PAP: Sipuleucel-T with or without pTVG-HP (100 μg)/ rhGM-CSF (200 μg)

Phase II (NCT01706458) N = 30

i.d.

PAP-specific Immunological response

[113]

PAP: rhGM-CSF (200 μg) with or without pTVG-HP (100 μg)

Phase II (NCT01341652) N = 56

i.d.

Metastasis-free survival

[114]

PSA: PROSTVAC with or without GM-CSF (100 μg)

Phase III (NCT01322490) N = 1200

s.c.

Overall Survival

[77]

PSA: Flutamide with or without PROSTVAC

Phase II (NCT00450463) N = 53

s.c.

Time to Treatment Failure

[115]

PSA: Adenovirus/PSA (1X10⁸ pfu in gelfoam)

Phase II (NCT00583024) N = 66

s.c.

PSA-DT Response

[76]

PSA: Adenovirus/PSA (1X10⁸ pfu in gelfoam) with or without ADT

Phase II (NCT00583752) N = 70

s.c.

PSA-DT Response

[116]